Table 3.
Overall survival and time to first therapy data of the MDACC PI, the CLL-IPI, and the Barcelona-Brno biomarkers only prognostic model risk groups.
| MDACC PI | ||||||
|---|---|---|---|---|---|---|
| Group | N | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p |
|
| ||||||
| Low risk | 160 | 238.5 (146–330.0) | 98.4 | 91.6 | 1 (ref) | |
| Intermediate risk | 302 | 142 (132–151.9) | 79.6 | 61.6 | 4.8 (2.6–9.1) | <0.0001 |
| High risk | 21 | 63.5 (52.6–74.4) | 51.1 | 15.3 | 5.3 (0–9.2) | <0.0001 |
|
| ||||||
| Group | N | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p |
|
| ||||||
| Low risk | 160 | 133.0 (110.8–155.3) | 20.3 | 47.5 | 1 (ref) | |
| Intermediate risk | 302 | 81 (46.6–115.4) | 44.9 | 55.7 | 2.2 (1.5–3.1) | <0.0001 |
| High risk | 21 | 2.3 (0.3–4.4) | 93.7 | 93.7 | 4.4 (3.2–6) | <0.0001 |
|
| ||||||
| CLL-IPI | ||||||
|
| ||||||
| Group | N | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p |
|
| ||||||
| Low risk | 126 | 238.5 (147–330) | 93.6 | 89.6 | 1 | |
| Intermediate risk | 79 | 144.8 (127.8–161.8) | 87.6 | 74.5% | 3.2 (1.5–6.7) | <0.0001 |
| High risk | 49 | 73.7 (56.6–90.7) | 67.8 | 26.8 | 2.2 (2.1–4.8) | <0.0001 |
| Very high risk | 7 | 31.8 (21.2–42.4) | 28.6 | NE∗ | 4.4 (3.2–6) | <0.0001 |
|
| ||||||
| Group | N | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p |
|
| ||||||
| Low risk | 126 | Not reached | 15.8 | 29.4 | 1 (ref) | |
| Intermediate risk | 79 | 52.9 (34.5–71.3) | 55 | 79.1 | 4.4 (2.7–7.2) | <0.0001 |
| High risk | 46 | 7.6 (5–10) | 93.4 | 93.4 | 3.7 (2.8–4.9) | <0.0001 |
| Very high risk | 7 | 9.6 (0–21) | NE∗∗ | NE∗∗ | 2.2 (1.6–3.2) | <0.0001 |
|
| ||||||
| Barcelona-Brno PI | ||||||
|
| ||||||
| Group | N | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p |
|
| ||||||
| Low risk | 145 | 238.5 (146.8–330) | 90.7 | 86 | 1 (ref) | |
| Intermediate risk | 91 | 131.9 (95–167.9) | 81.4 | 61.1 | 4.34 (2.85–6.63) | <0.0001 |
| High risk | 22 | Not reached | 66.2 | 53 | 9.37 (5.12–17.14) | <0.0001 |
|
| ||||||
| Group | N | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p |
|
| ||||||
| Low risk | 142 | 182.2 (83.9–280.4) | 19.9 | 35.8 | 1 (ref) | |
| Intermediate risk | 91 | 31.5 (14.4–48.5) | 64.7 | 82.4 | 2.95 (1.57–5.52) | <0.0001 |
| High risk | 21 | 9.8 (2.4–17.2) | 91.6 | 91.6 | 4.24 (1.67–10.97) | <0.0001 |
NE: not evaluable. NE∗: last control in month 94. NE∗∗: last control in month 45. MDACC: MD Anderson Cancer Center. CLL-IPI: chronic lymphocytic leukemia international prognostic index.